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ABSTRACT
Objectives To evaluate efficacy and safety of 
immediate switch from upadacitinib to adalimumab, or 
vice versa, in patients with rheumatoid arthritis with non- 
response or incomplete- response to the initial therapy.
Methods SELECT- COMPARE randomised patients to 
upadacitinib 15 mg once daily (n=651), placebo (n=651) 
or adalimumab 40 mg every other week (n=327). A 
treat- to- target study design was implemented, with 
blinded rescue occurring prior to week 26 for patients 
who did not achieve at least 20% improvement in both 
tender and swollen joint counts (’non- responders’) and 
at week 26 based on Clinical Disease Activity Index 
(CDAI) >10 (’incomplete- responders’) without washout.
Results A total of 39% (252/651) and 49% (159/327) 
of patients originally randomised to upadacitinib and 
adalimumab were rescued to the alternate therapy. In 
both switch groups (adalimumab to upadacitinib and 
vice versa) and in non- responders and incomplete- 
responders, improvements in disease activity were 
observed at 3 and 6 months following rescue. CDAI low 
disease activity was achieved by 36% and 47% of non- 
responders and 45% and 58% of incomplete- responders 
switched to adalimumab and upadacitinib, respectively, 
6 months following switch. Overall, approximately 5% 
of rescued patients experienced worsening in disease 
activity at 6 months postswitch. The frequency of adverse 
events was similar between switch groups.
Conclusions These observations support a treat- to- 
target strategy, in which patients who fail to respond 
initially (or do not achieve sufficient response) are 
switched to a therapy with an alternate mechanism 
of action and experience improved outcomes. No new 
safety findings were observed despite immediate switch 
without washout.
INTRODUCTION
It is recommended that the rheumatoid arthritis 
(RA) treatment paradigm use a treat- to- target 
strategy in which therapy is optimised every 3–6 
months until clinical remission, or at minimum, 
low disease activity (LDA) is achieved.1–5 For 
patients who do not achieve these goals with 
conventional synthetic disease- modifying antirheu-
matic drugs (csDMARDs), both American College 
of Rheumatology (ACR) and European League 
Against Rheumatism (EULAR) guidelines suggest 
the addition of a biological DMARD (bDMARD) 
or a targeted synthetic DMARD (tsDMARD).2 3 If 
patients continue to exhibit unacceptable disease 
Key messages
What is already known about this subject?
 ► In patients with rheumatoid arthritis, a treat- 
to- target strategy is recommended, in which 
therapy is optimised every 3–6 months until 
remission, or low disease activity, is achieved. 
Recent treatment recommendations suggest the 
addition of a biological or targeted- synthetic 
disease- modifying antirheumatic drug in 
patients who do not achieve treatment goals, 
and switches between mechanisms of action 
occur commonly in clinical practice.
 ► The SELECT- COMPARE study followed treat- to- 
target principles. Patients were blindly switched 
from upadacitinib, a Janus kinase (JAK) 
inhibitor, to adalimumab, a tumour necrosis 
factor (TNF) inhibitor, and vice versa following 
insufficient response to the initial therapy. 
Previously reported high- level efficacy data 
from this study showed that patients switched 
to either agent experienced improved response 
following switch.
What does this study add?
 ► This observation from SELECT- COMPARE 
provides clinically relevant and detailed switch 
efficacy data in the subgroups of patients 
who switched due to initial non- response or 
incomplete- response. Following a blinded 
switch in mechanism of action, more patients 
were able to achieve treatment goals of 
remission and low disease activity, in both 
the non- responder and incomplete- responder 
groups. This study also reports minimal risk of 
flare following a switch in treatment.
 ► Additionally, not previously reported, unique 
and important details on the safety of an 
immediate switch from a JAK inhibitor to a TNF 
inhibitor are also provided. This study revealed 
no new safety signals despite an immediate 
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activity, a switch to a different bDMARD, or to a tsDMARD, 
is recommended. Although therapeutic options continue to 
increase, many patients with RA do not achieve stringent treat-
ment goals. Therefore, data on the effectiveness and safety of 
switching between different mechanisms of action (MoAs) have 
become increasingly important. Results from controlled trials 
suggest that patients with insufficient response to a bDMARD 
may respond to a Janus kinase inhibitor (JAKi).6–9 In contrast, 
there is limited evidence regarding the efficacy and safety of 
switching patients to a tumour necrosis factor inhibitor (TNFi) 
following insufficient response to a JAKi.10
Upadacitinib, an oral JAKi, has been studied across various 
patient populations in RA, including methotrexate (MTX)- 
inadequate responders in SELECT- COMPARE.11–13 The most 
recent EULAR recommendations for RA treatment address the 
shifting therapeutic paradigm.3 This study employed a unique 
rescue strategy, permitting blinded rescue from upadacitinib to 
adalimumab, and vice versa, in the subgroup of patients who did 
not achieve treatment targets with their initial therapy. Although 
preliminary data on an immediate switch from either a TNFi to a 
JAKi or vice versa have been reported,10 11 the safety of an imme-
diate switch and the efficacy of a switch from a JAKi to a TNFi 
in patients who either do not have an initial response or experi-
ence an insufficient response have not been fully described. The 
present observational analysis describes the efficacy and safety 
results of the application of this treat- to- target strategy and 
expands significantly on the limited results reported previously.10
PATIENTS AND METHODS
Patients
Eligibility criteria have been described previously.11 Briefly, 
adult patients with RA with ≥6 swollen and ≥6 tender joints, a 
high- sensitivity C- reactive protein (hsCRP) level ≥5 mg/L, and 
evidence of erosive disease and/or seropositivity for either rheu-
matoid factor or anticyclic citrullinated peptide antibodies were 
enrolled.
Study design
Patients were randomised to double- blinded upadacitinib 15 mg 
once daily, placebo or adalimumab 40 mg every other week with 
background MTX (online supplemental figure S1). Blinded rescue 
(upadacitinib to adalimumab, adalimumab to upadacitinib and 
placebo to upadacitinib) occurred prior to week 26 (weeks 14, 
18 or 22) for patients who did not achieve ≥20% improvement 
from baseline in both tender and swollen joint count based on 68 
joints (TJC68) or 66 joints (SJC66) (defined as ‘non- responders’ 
(NR)). An additional blinded switch occurred at week 26 for 
patients who did not achieve Clinical Disease Activity Index 
(CDAI) LDA (≤10; defined as ‘incomplete- responders’ (IR)). 
Rescue was immediate and without washout according to the 
following schedule: (1) switching to upadacitinib: last dose of 
adalimumab was administered 2 weeks prior to starting upad-
acitinib; (2) switching to adalimumab: adalimumab was injected 
1 day after the last dose of upadacitinib. Each patient could 
only be switched once. Further details on the blinded rescue are 
provided in the online supplemental text. The observations of 
efficacy and safety of patients switching between upadacitinib 
and adalimumab (and vice versa) are presented here.
The study was conducted in accordance with the International 
Conference on Harmonization guidelines, applicable regulations 
and the Declaration of Helsinki. All patients provided written 
informed consent.
Assessments
Efficacy was evaluated up to 6 months (±2 weeks) postswitch 
using validated outcome measures including ACR response 
criteria (ACR20/50/70 (improvement of ≥20%, 50% and 70% 
in ACR criteria)); CDAI LDA (≤10) and remission (≤2.8); 
28- joint Disease Activity Score based on C- reactive protein 
(DAS28(CRP))≤3.2 and<2.6 and change from baseline in 
Health Assessment Questionnaire- Disability Index (HAQ- DI), 
patient assessment of pain (0–100 mm visual analogue scale), 
TJC68, SJC66, Patient’s Global Assessment of Disease Activity 
(PtGA), Physician’s Global Disease Activity (PhGA) and hsCRP. 
Response criteria and change from baseline were evaluated as 
change from original baseline value at randomisation.
Disease worsening after switch was determined based on 
DAS28(CRP) increase >0.6 or >1.2 from rescue, evaluated at 3 
and 6 months following rescue.14
Treatment- emergent adverse events (TEAEs) were evaluated 
0–3 months postswitch to assess the safety of an immediate 
switch and, separately, 4–6 months following switch.10 11 To 
better understand the safety preswitch and postswitch, TEAEs 
were evaluated for the same patients both before and after 
switch. In this analysis, a matching follow- up period was used to 
ensure a consistent evaluation across patients who were rescued 
at different time points. Finally, TEAEs were also evaluated in 
patients who switched and those who remained on continuous 
therapy using matching time periods.
Statistical analysis
For these observations, descriptive statistics are summarised for 
the NR and IR treatment groups following switch. As rescue 
groups were not randomised for this subset of patients, no direct 
statistical comparison was made between groups. The study was 
not designed to compare efficacy or safety between the switch 
treatment arms. Data are reported as observed with no imputa-
tion for missing data. Adverse event data are reported as n (%) 
with 95% CIs.
Sensitivity analyses were conducted to exclude the few 
patients in the IR group who were rescued at week 26 despite 
the achievement of CDAI LDA. Spearman correlation and a 
univariate logistic regression analysis were used to assess the 
association between baseline disease characteristics and ‘double 
non- response’, defined as patients who required rescue (at any 
time point) and still failed to achieve CDAI LDA at both 3 and 6 
months postswitch.
RESULTS
Of the 651 patients randomised to upadacitinib and 327 patients 
randomised to adalimumab, 38.7% (252/651) and 48.6% 
(159/327), respectively, were rescued to the alternate therapy 
prior to week 26 due to NR or at week 26 due to IR (figure 1). 
Across both treatment groups, roughly equal proportions of 
patients were rescued due to NR and IR.
Key messages
How might this impact on clinical practice or future 
developments?
 ► Findings here indicate that an immediate switch in 
mechanism of action (from a JAK inhibitor to a TNF inhibitor 
and vice versa) following treat- to- target principles is feasible 
with minimal risk of flare regardless of whether patients 
are switched due to non- response or incomplete- response 
without an increase in clinically meaningful adverse events.
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Baseline demographics were generally similar between patients 
who were switched and the overall study population.11 There 
was improvement in disease activity assessments from baseline 
to the time of switch, and the improvements were greater in 
the IR patients compared with patients in the NR group (online 
supplemental table S1).
Non-responders
A switch in MoA had a beneficial effect on clinical responses in 
both groups. Six months after rescue, 59.3% (67/113)/25.9% 
(29/112)/12.3% (14/114) of patients achieved ACR20/50/70 
responses following rescue to adalimumab and 74.6% 
(53/71)/49.3% (34/69)/23.6% (17/72) following rescue to upad-
acitinib (figure 2). CDAI LDA and remission were achieved by 
36.0% (41/114) and 5.3% (6/114) of patients after rescue to 
adalimumab and 47.1% (33/70) and 14.3% (10/70) of patients 
after rescue to upadacitinib (figure 3). Six months after rescue 
to adalimumab, DAS28(CRP) ≤3.2 and DAS28(CRP) <2.6 
were achieved by 34.9% (38/109) and 19.3% (21/109) of 
patients; 54.3% (38/70) and 31.4% (22/70) of patients achieved 
DAS28(CRP) ≤3.2 and DAS28(CRP) <2.6 at 6 months after 
rescue to upadacitinib (figure 3). There were also improve-
ments from baseline in function (HAQ- DI), joint counts (TJC68/
SJC66), patient and physician global assessments (PtGA, PhGA, 
pain) and hsCRP following rescue to the alternate agent (online 
supplemental figure S2).
Some NR experienced increases in disease activity following 
rescue: at 6 months postrescue, 12.4% (13/105) and 7.4% (5/68) 
of those switched to adalimumab and upadacitinib, respectively, 
had an increase in DAS28(CRP) >0.6. Eight (4.6%; 8/173) of 
all NR (6 rescued to adalimumab and 2 rescued to upadacitinib) 
experienced a worsening in DAS28(CRP) >1.2 (figure 4).
Incomplete-responders
Six months after switch to adalimumab, 77.3% (92/119)/46.7% 
(56/120)/18.5% (22/119) of IR achieved ACR20/50/70 
responses; of those switched to upadacitinib, 86.7% 
(65/75)/62.5% (45/72)/39.2% (29/74) achieved ACR20/50/70 
at 6 months following switch (figure 2). As expected, given that 
incomplete- responders by definition had at least 20% improve-
ment in TJC and SJC at the rescue visits prior to week 26, 
most had achieved an ACR20 response at switch. At 6 months 
following switch, CDAI LDA and remission were achieved 
by 45.0% (54/120) and 5.0% (6/120) of patients switched to 
adalimumab and 57.9% (44/76) and 15.8% (12/76) of patients 
switched to upadacitinib (figure 3). Among patients switched 
to adalimumab, 43.8% (53/121) and 23.1% (28/121) achieved 
DAS28(CRP) ≤3.2 and DAS28(CRP) <2.6 at 6 months 
Figure 1 Proportion of patients rescued. *12% (78/651), 5% (29/651) 
and 3% (19/651) of patients were rescued from UPA to ADA at W14, 
W18 and W22, respectively. 17% (56/327), 4% (14/327) and 2% (7/327) 
were rescued from ADA to UPA at W14, W18 and W22, respectively. 
ADA, adalimumab; CDAI, Clinical Disease Activity Index; LDA, low 
disease activity; SJC66, swollen joint count-66 joints; TJC68, tender joint 
count-68 joints; UPA, upadacitinib; W, week.
Figure 2 Percentage of non- responders (A) and incomplete- responders (B) achieving ACR20/50/70 at 3 and 6 months postswitch. All data points are 
provided in online supplemental table S6. ACR20/50/70, improvement of at least 20%, 50% and 70% in American College of Rheumatology criteria 
from baseline; ADA, adalimumab; mo, month; UPA, upadacitinib.
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postswitch; 57.1% (44/77) and 37.7% (29/77) of patients 
switched to upadacitinib achieved DAS28(CRP) ≤3.2 and<2.6 
(figure 3). In addition, when switched to the alternate therapy, 
an improvement from baseline was observed in HAQ- DI, 
TJC68/SJC66, PtGA, PhGA, pain and hsCRP (online supple-
mental figure S2).
Following switch, some IR experienced a worsening in disease. 
At 6 months postrescue, 19.8% (24/121) and 3.9% (3/77) of 
patients switched to adalimumab and upadacitinib, respectively, 
experienced an increase in DAS28(CRP) >0.6. (figure 4). At the 
same time point, 9 (4.5%; 9/198) of all IR (8 switched to adali-
mumab and 1 switched to upadacitinib) experienced a clinically 
relevant worsening of DAS28(CRP) >1.2.14
In the IR group, 7.1% (9/126) of patients switched to adali-
mumab and 6.1% (5/82) of patients switched to upadacitinib 
were switched despite achievement of CDAI LDA. Results were 
unchanged when these patients were excluded from the analyses 
(online supplemental table S2).
Double non-response
Correlation and logistic regression analyses were conducted to 
evaluate potential factors associated with double non- response. 
In total, 210 patients (21.2% (138/651) and 22.0% (72/327) of 
patients initially randomised to upadacitinib or adalimumab, 
respectively) were double non- responders. Both analyses showed 
a weak association between higher disease activity and func-
tional impairment at baseline and double non- response (online 
supplemental tables S3 and S4). No other discriminators were 
observed.
Safety
Following immediate switch in treatment without washout, 
the proportion of patients experiencing any TEAE was similar 
regardless of whether patients switched to adalimumab or 
upadacitinib (table 1). The frequency of infections, including 
serious infections, and herpes zoster was also similar between 
switch groups. No active tuberculosis, non- melanoma skin 
cancer, adjudicated major adverse cardiovascular event, or 
deaths were reported. Additionally, no differences in the 
proportion of TEAEs were observed when the same patient 
groups were evaluated prior to and following rescue (table 2). 
Similarly, no meaningful differences in TEAEs were observed 
in patients who switched therapy compared with those who 
remained on continuous therapy (online supplemental table 
S5).
Figure 3 Percentage of non- responders and incomplete- responders 
achieving CDAI LDA (A) and remission (B), and DAS28(CRP)≤3.2 (C) and 
<2.6 (D) at 3 and 6 months postswitch. All data points are provided in 
online supplemental table S7. ADA, adalimumab; CDAI, Clinical Disease 
Activity Index; DAS28(CRP), 28- joint Disease Activity Score based on 
C- reactive protein; LDA, low disease activity; UPA, upadacitinib.
Figure 4 Percentage of non- responders and incomplete- responders with DAS28(CRP) change from switch >0.6 (A) and >1.2 (B). ADA, adalimumab; 
DAS28(CRP), 28- joint Disease Activity Score based on C- reactive protein; UPA, upadacitinib.
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DISCUSSION
Recent advances in drug development have led to approval of 
multiple therapeutic options, including oral therapies, for RA. 
Recommendations from professional societies have noted the 
importance of the availability of a variety of MoAs and discuss 
switching MoAs in the event of insufficient response.2 3 While 
there are multiple reports of switching to an alternative agent 
following inadequate response to a TNFi, there are no other data 
on an immediate switch in MoA following insufficient response 
to a JAKi. This poses a challenge for clinicians making evidence- 
based treatment decisions. The unique trial design of SELECT- 
COMPARE, the first fully blinded study to report switch data 
between a JAKi and a TNFi, permitted assessment of these ques-
tions in a setting with defined criteria and provides the first data 
showing clinical outcomes in patients who failed to respond to a 
JAKi and subsequently switched to a TNFi. In contrast to another 
JAKi trial where patients were not rescued from the JAKi to 
adalimumab, SELECT- COMPARE provides data with a rescue 
in both directions based on objective and predefined criteria.15 
Ultimately, the observations from SELECT- COMPARE provide 
valuable outcomes for providers using treat- to- target principles 
for their patients who continue to manifest active disease despite 
treatment with a TNFi and highlights the importance of diverse 
MoAs.
In the present analysis, many patients with initial NR or IR 
to either upadacitinib or adalimumab experienced meaningful 
improvement in clinical and functional outcomes following 
rescue to the alternate therapy, suggesting that a switch to either 
MoA may be beneficial for patients with RA not previously 
meeting treatment goals. Clinically relevant improvements from 
baseline across different disease measures were consistently seen 
in both groups, although numerically better improvement was 
generally observed in IR versus NR patients. The data observed 
for patients switching from adalimumab to upadacitinib were in 
line with previously reported data from the SELECT- BEYOND 
trial, which evaluated upadacitinib in bDMARD- inadequate 
responder patients.6 Similarly, the outcomes observed for patients 
switching from upadacitinib to adalimumab were consistent 
with those reported in the EXXELERATE study where patients 
were switched to adalimumab following inadequate response 
to an alternate TNFi.16 Studies involving bDMARD- inadequate 
responder patients, such as SELECT- BEYOND, used prolonged 
intervals between the stop of biological therapy and initiation of 
JAKi for perceived safety concerns; the observations in SELECT- 
COMPARE provide direct switch data with no washout period 
suggesting that an immediate switch did not lead to increased 
safety concerns. The safety of immediate switch between adali-
mumab and upadacitinib seen here is in line with prior safety 
experience of an immediate switch between two TNFis seen in 
EXXELERATE.16
As with all therapies, there was a proportion of patients 
who either had little if any initial response or who improved 
but failed to achieve disease targets. A potential concern with 
switching therapies in the latter group is whether their disease 
will worsen on a change in therapy. In the present analysis, rela-
tively few patients experienced a clinically significant worsening 
Table 1 Number and percentage of patients experiencing TEAEs 0–3 months and 4–6 months post- treatment switch
Adverse events no. (%) (95% CI)
0–3 months postswitch 4–6 months postswitch
UPA 15 mg to ADA (n=252) ADA to UPA 15 mg (n=159) UPA 15 mg to ADA (n = 252) ADA to UPA 15 mg (n=159)
Any AE 125 (49.6) (43.5 to 55.7) 64 (40.3) (33.0 to 48.0) 90 (35.7) (30.1 to 41.8) 58 (36.5) (29.4 to 44.2)
Serious AE 6 (2.4) (1.1 to 5.1) 6 (3.8) (1.7 to 8.0) 11 (4.4) (2.5 to 7.7) 9 (5.7) (3.0 to 10.4)
AE leading to D/C 7 (2.8) (1.4 to 5.6) 3 (1.9) (0.6 to 5.4) 8 (3.2) (1.6 to 6.1) 5 (3.1) (1.4 to 7.2)
Deaths 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 1.5) 0 (0.0 to 2.4)
Infection 41 (16.3) (12.3 to 21.3) 30 (18.9) (13.6 to 25.7) 46 (18.3) (14.0 to 23.5) 29 (18.2) (13.0 to 25.0)
  Serious infection* 2 (0.8) (0.2 to 2.9) 4 (2.5) (1.0 to 6.3) 3 (1.2) (0.4 to 3.4) 2 (1.3) (0.4 to 4.5)
  Opportunistic infection 0 (0.0 to 1.5) 1 (0.6) (0.1 to 3.5) 0 (0.0 to 1.5) 1 (0.6) (0.1 to 3.5)
  Herpes zoster 1 (0.4) (0.1 to 2.2) 2 (1.3) (0.4 to 4.5)† 2 (0.8) (0.2 to 2.9) 2 (1.3) (0.4 to 4.5)
  TB‡ 0 (0.0 to 1.5) 0 (0.0 to 2.4) 7 (2.8) (1.4 to 5.6) 3 (1.9) (0.6 to 5.4)
Malignancy (excluding NMSC) 0 (0.0 to 1.5) 1 (0.6) (0.1 to 3.5) 1 (0.4) (0.1 to 2.2) 0 (0.0 to 2.4)
  NMSC 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 1.5) 0 (0.0 to 2.4)
GI perforation§ 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 1.5) 1 (0.6) (0.1 to 3.5)
Adjudicated MACE 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 1.5) 0 (0.0 to 2.4)
Adjudicated VTE¶ 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 1.5) 1 (0.6) (0.1 to 3.5)
Hepatic disorder** 8 (3.2) (1.6 to 6.1) 4 (2.5) (1.0 to 6.3) 8 (3.2) (1.2 to 6.1) 2 (1.3) (0.4 to 4.5)
Anaemia 3 (1.2) (0.4 to 3.4) 2 (1.3) (0.4 to 4.5) 1 (0.4) (0.1 to 2.2) 2 (1.3) (0.4 to 4.5)
Neutropaenia 4 (1.6) (0.6 to 4.0) 2 (1.3) (0.4 to 4.5) 2 (0.8) (0.2 to 2.9) 1 (0.6) (0.1 to 3.5)
Lymphopaenia 1 (0.4) (0.1 to 2.2) 1 (0.6) (0.1 to 3.5) 1 (0.4) (0.1 to 2.2) 0 (0.0 to 2.4)
CPK elevation 2 (0.8) (0.2 to 2.9) 0 (0.0 to 2.4) 1 (0.4) (0.1 to 2.2) 1 (0.6) (0.1 to 3.5)
0–3 months postswitch is from first dose of study drug to day 91; 4–6 months postswitch is from day 92 to 183.
Values are the number (%) of patients with events. CIs are calculated using the Wilson method.
*0–3 months postswitch UPA to ADA: pneumonia, tonsillitis, ADA to UPA: upper respiratory tract infection, herpes zoster, cellulitis and one patient with oral herpes, sepsis and pneumonia. 
4–6 months postswitch UPA to ADA: diverticulitis, uveitis, pyelonephritis, ADA to UPA: latent TB, pneumonia.
†46- year- old patient without a history of herpes zoster vaccination and on background glucocorticoid and methotrexate therapy developed a serious herpes zoster infection in the face 
affecting one dermatome. Upadacitinib could be restarted after successful antiviral treatment with acyclovir.
‡All cases were latent TB.
§GI perforations were identified through Standardised Medical Dictionary for Regulatory Activities query. The one event in a patient rescued to upadacitinib was not a spontaneous GI 
perforation but an event of anal fistula.
¶One patient experienced a venous thromboembolism (pulmonary embolism) 4–6 months after switch to upadacitinib; this patient had risk factors (smoker, previous deep vein thrombosis) 
and upadacitinib was permanently discontinued.
**Majority of hepatic disorders were asymptomatic alanine aminotransferase/aspartate aminotransferase elevations.
ADA, adalimumab; AE, adverse event; CPK, creatine phosphokinase; D/C, discontinuation; GI, gastrointestinal; MACE, major adverse cardiovascular event; NMSC, non- melanoma skin cancer; 
TB, tuberculosis; TEAE, treatment- emergent adverse event; UPA, upadacitinib; VTE, venous thromboembolism.
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in disease following switch. Six months following rescue for 
either incomplete- response or non- response, only approxi-
mately 5% of patients rescued to either therapy (adalimumab to 
upadacitinib or vice versa) experienced a worsening in disease 
as defined by an increase in DAS28(CRP) >1.2. In SELECT- 
COMPARE, this flare risk is largely outweighed by the observed 
efficacy outcomes. Approximately one- half of patients who had 
a clinically relevant response with a significant decrease in CDAI, 
but did not achieve CDAI LDA, were able to achieve this strin-
gent endpoint with a switch in MoA. These outcomes support a 
treat- to- target strategy, and address a common question asked in 
clinical practice regarding the likelihood of a patient achieving 
treatment goals with a switch in therapy versus the chances 
of them experiencing disease worsening. The current analysis 
would suggest that a switch is much more likely to be successful 
than the risk of a flare.
There were patients who did not respond to either therapy. 
Based on exploratory analyses examining baseline demographics, 
predictors for double non- response could not be identified; 
additional research is needed to elucidate predictors of patients 
who will fail to respond to either therapy.
Although it may appear that the proportion of patients rescued 
in this study (in total, 252 patients (39%) rescued to adalimumab 
and 159 patients (49%) rescued to upadacitinib) is greater than 
rescue rates observed in other trials, this was largely due to the 
unique rescue scheme used in SELECT- COMPARE. Treatment 
switch was permitted at four time points and included rescue 
based on the stringent metric of CDAI LDA at week 26. Other 
studies typically only permitted rescue at a single time point.17–19 
In these studies, the rates of rescue are consistent with those 
described at week 14 for SELECT- COMPARE.
This analysis also provides clinically relevant, blinded data on 
the safety of an immediate switch in therapy from a biological 
to a JAKi without washout. Given a mean terminal half- life of 
approximately 2 weeks for adalimumab,20 21 pharmacodynamic 
(PD) effects might persist to a certain degree after discontinuation 
of adalimumab until complete washout within several weeks. On 
the other hand, upadacitinib has a shorter half- life of 9–14 hours 
and immediate PD effects (eg, those based on IL-6 signalling) 
are expected to disappear within a day.22 Complete washout of 
upadacitinib is expected within a few days; however, delayed PD 
effect may last beyond this. While there is potential for differ-
ences in the overlap of inhibition between the two switch arms, 
overall efficacy appears consistent through 6 months with no 
fluctuations in response. Clinically, consideration for half- life 
and PD effects may need to be given for individual patients. 
Importantly, in terms of safety, although limited by sample size, 
based on available data from over 400 patients, no additional 
safety concerns were observed in either treatment group (upad-
acitinib to adalimumab and vice versa) despite this immediate 
switch. In particular, and perhaps most pertinent considering 
overlapping PD effects, no differences in frequency of infections 
were observed between treatment groups at both 0–3 and 4–6 
months postrescue. Overall consistent findings were observed 
in the adverse event profile of patients evaluated prior to and 
following switch.
This study is not without limitations. Due to the observa-
tional nature of this analysis, both the safety and efficacy evalu-
ations are ultimately limited by the number of patients who met 
rescue criteria; as such, the present analysis was not designed 
or powered for statistical comparisons between switch groups 
(either the two switch arms, or NR versus IR) and the results 
should be interpreted as observational. Additionally, this anal-
ysis from a clinical trial population may not be generalisable to 
all patients in clinical practice; further real- world studies are 
needed to confirm these results. While the study used aspects 
of a treat- to- target strategy, the rescue was based on predefined 
criteria at specified timepoints, and did not allow providers 
the opportunity to adjust therapy more freely in accordance 
with their clinical judgement, as may be more typical of a true 
Table 2 Number and percentage of patients experiencing TEAEs in patients prior to and following treatment switch
Adverse events, no. (%) (95% CI)
UPA 15 mg to ADA (n = 252) ADA to UPA 15 mg (n = 159)
Prior to switch (UPA 15 mg) After switch (ADA) Prior to switch (ADA) After switch (UPA 15 mg)
Any AE 163 (64.7) (58.6 to 70.3) 152 (60.3) (54.2 to 66.2) 91 (57.2) (49.5 to 64.7) 85 (53.5) (45.7 to 61.0)
Serious AE 10 (4.0) (2.2 to 7.2) 12 (4.8) (2.7 to 8.1) 3 (1.9) (0.6 to 5.4) 10 (6.3) (3.5 to 11.2)
AE leading to D/C NA 12 (4.8) (2.7 to 8.1) NA 8 (5.0) (2.6 to 9.6)
Deaths 0 (0.0 to 1.5) 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 2.4)
Infection 79 (31.3) (26.0 to 37.3) 65 (25.8) (20.8 to 31.5) 36 (22.6) (16.8 to 29.8) 38 (23.9) (17.9 to 31.1)
  Serious infection 5 (2.0) (0.9 to 4.6) 4 (1.6) (0.6 to 4.0) 1 (0.6) (0.1 to 3.5) 4 (2.5) (1.0 to 6.3)
  Opportunistic infection 3 (1.2) (0.4 to 3.4) 0 (0.0 to 1.5) 0 (0.0 to 2.4) 1 (0.6) (0.1 to 3.5)
  Herpes zoster 2 (0.8) (0.2 to 2.9) 2 (0.8) (0.2 to 2.9) 0 (0.0 to 2.4) 3 (1.9) (0.6 to 5.4)
  TB 0 (0.0 to 1.5) 7 (2.8) (1.4 to 5.6) 0 (0.0 to 2.4) 1 (0.6) (0.1 to 3.5)
Malignancy (excluding NMSC) 0 (0.0 to 1.5) 0 (0.0 to 1.5) 0 (0.0 to 2.4) 1 (0.6) (0.1 to 3.5)
  NMSC 0 (0.0 to 1.5) 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 2.4)
GI perforation 0 (0.0 to 1.5) 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 2.4)
Adjudicated MACE 0 (0.0 to 1.5) 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 2.4)
Adjudicated VTE 2 (0.8) (0.2 to 2.9) 0 (0.0 to 1.5) 0 (0.0 to 2.4) 0 (0.0 to 2.4)
Hepatic disorder 17 (6.7) (4.3 to 10.6) 13 (5.2) (3.0 to 8.6) 6 (3.8) (1.7 to 8.0) 5 (3.1) (1.4 to 7.2)
Anaemia 2 (0.8) (0.2 to 2.9) 5 (2.0) (0.9 to 4.6) 4 (2.5) (1.0 to 6.3) 3 (1.9) (0.6 to 5.4)
Neutropaenia 6 (2.4) (1.1 to 5.1) 6 (2.4) (1.1 to 5.1) 2 (1.3) (0.4 to 4.5) 2 (1.3) (0.4 to 4.5)
Lymphopaenia 2 (0.8) (0.2 to 2.9) 2 (0.8) (0.2 to 2.9) 2 (1.3) (0.4 to 4.5) 1 (0.6) (0.1 to 3.5)
CPK elevation 12 (4.8) (2.7 to 8.1) 3 (1.2) (0.4 to 3.4) 0 (0.0 to 2.4) 4 (2.5) (1.0 to 6.3)
Before switch time period is defined as day one to date of switch; post switch time period is defined as the day after switch to 99, 127, 155, and 183 days after switch for the patients who 
switched at weeks 14, 18, 22, and 26, respectively.
Values are the number (%) of patients with events. CIs are calculated using the Wilson method.
ADA, adalimumab; AE, adverse event; CPK, creatine phosphokinase; D/C, discontinuation; GI, gastrointestinal; MACE, major adverse cardiovascular event; NA, not applicable; NMSC, non- 
melanoma skin cancer; TB, tuberculosis; TEAE, treatment- emergent adverse event; UPA, upadacitinib; VTE, venous thromboembolism.
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treat- to- target strategy. Patients were not rerandomised at rescue 
but were switched to the alternate treatment in a double- blind 
fashion using an interactive response technology system.
In summary, SELECT- COMPARE used a treat- to- target 
strategy with blinded rescue and provides the first data to suggest 
patients switching from a JAKi to a TNFi may experience an 
improved response following rescue. Patients with initial NR or 
IR to either upadacitinib 15 mg once daily or adalimumab 40 mg 
every other week, both in combination with MTX, showed 
benefit in both clinical and functional outcomes when switched 
to the alternate therapy. Numerous patients who had a signifi-
cant clinical response but did not reach CDAI LDA were able to 
reach this target with a switch in MoA. Despite an immediate 
switch in MoA, without washout, no new safety signals were 
observed in either treatment group.23
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